LY-344545
LY-344545 is a pharmacological compound that acts as a selective antagonist for the NMDA receptor, a type of glutamate receptor. It has been studied for its potential use in the treatment of various neurological disorders, including schizophrenia and Alzheimer's disease.
Pharmacology[edit]
LY-344545 is a non-competitive antagonist of the NMDA receptor, which means it binds to a site on the receptor that is distinct from the agonist binding site. This prevents the activation of the receptor by glutamate, the primary excitatory neurotransmitter in the central nervous system.
Clinical significance[edit]
The NMDA receptor is implicated in a variety of neurological and psychiatric disorders, including schizophrenia, Alzheimer's disease, and major depressive disorder. Antagonists of the NMDA receptor, such as LY-344545, have therefore been investigated for their potential therapeutic effects.
Schizophrenia[edit]
In schizophrenia, there is evidence of dysfunction in glutamatergic neurotransmission, and specifically in the function of the NMDA receptor. LY-344545, as an NMDA receptor antagonist, has been studied for its potential to alleviate the symptoms of schizophrenia.
Alzheimer's disease[edit]
The role of the NMDA receptor in Alzheimer's disease is less clear, but it is thought that overactivation of the receptor may contribute to the neurodegeneration seen in this condition. LY-344545 may therefore have potential as a treatment for Alzheimer's disease.
See also[edit]
References[edit]
-
LY-344545 Structure
Sponsored Health Resource
W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
